Drug intelligence / Profile preview

Streptococcus thermophilus IHA318

Development stage: Preclinical
Lead developer: Percheron Bioceutical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Streptococcus thermophilus iHA318 is a specific probiotic strain investigated for its therapeutic potential in managing dry eye syndrome (DES). Administered orally, this live biotherapeutic product is thought to exert its effects through a gut-immune-ocular axis. A clinical trial (NCT05906381) in participants with DES demonstrated that daily intake of iHA318 for 35 days led to significant improvements in clinical signs and symptoms, including increased tear volume, improved tear osmolarity, and prolonged tear break-up time. The proposed mechanism involves modulation of the gut microbiota, which leads to systemic anti-inflammatory effects, including the suppression of NLRP3 inflammasome activation on the ocular surface. Additionally, an increase in serum sialic acid levels was observed, suggesting a potential enhancement of the mucin response and tear film stability.

Other names: Streptococcus thermophilus iHA318

Targets

NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)

Beyond the preview

Go deeper on Streptococcus thermophilus IHA318.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus thermophilus IHA318.

Explore the full profile